Group 1 - The company announced a leadership change effective December 19, 2025, with Mr. Zhang Cuilong stepping down as Vice Chairman, CEO, and authorized representative due to job relocation, but will remain an executive director [1] - Dr. Cai Lei has been appointed as Vice Chairman, Executive Director, CEO, and authorized representative [1] - Mr. Wei Qingjie has been appointed as Vice Chairman, Executive Director, and Chief Operating Officer [1]

Core Viewpoint - The announcement from the company indicates significant changes in its leadership structure, effective December 19, 2025, which may impact its strategic direction and operational management [1] Group 1: Leadership Changes - Zhang Cuilong will no longer serve as Vice Chairman, CEO, and authorized representative due to job relocation but will remain an executive director [1] - Cai Lei has been appointed as Vice Chairman, Executive Director, CEO, and authorized representative [1] - Wei Qingjie has been appointed as Vice Chairman, Executive Director, and Chief Operating Officer [1]

智通财经APP讯，石药集团(01093)发布公告，自2025年12月19日起生效：张翠龙先生因工作调动而不再 担任董事会副主席、公司首席执行官及根据香港联合交易所有限公司证券上市规则第3.05条项下公司授 权代表，但将继续担任公司执行董事;蔡磊博士获委任为副主席、公司执行董事、首席执行官及授权代 表;魏青杰先生获委任为副主席、公司执行董事及首席运营官。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 SYH2085片在中國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布 ， 本 集 團 開 發 的 SYH2085 片（「 該 產 品 」）已 獲 得 中 華 人 民 共 和 國 國 家 藥 品 監 督 管 理 局 批 准，可在中國開展臨床試驗。 該 產 品 為 本 集 團 自主 研 發 的 化 學 1 類創 新 藥 ， 是 一 款 可 抑 制 流 感 病 毒的 RNA 聚 合 酶 酸 性 蛋 白(PA)核酸內切酶活性的新型口服小分子候選藥物。本次獲批的臨床適應症為用於治療成 人及12歲以上青少年單純性甲型和乙型流感。臨床 ...

蔡東晨先生 （ 主席 ） 蔡磊博士 （ 副主席及首席執行官 ） 魏青杰先生 （ 副主席及首席運營官 ） 張翠龍先生 王振國先生 王懷玉先生 李春雷博士 姚兵博士 蔡鑫先生 陳衛平先生 屈志勇先生 獨立非執行董事： 王波先生 CHEN Chuan先生 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 董事名單與其角色和職能 石藥集團有限公司董事會（「董事會」）成員載列如下： 執行董事： M 有關董事委員會的成員 香港，2025年12月19日 王宏廣教授 歐振國先生 羅卓堅先生 李泉女士 下表提供董事會成員在董事委員會中所擔任的職位： | 董事委員會 | | | | | --- | --- | --- | --- | | 董事 | 審核委員會 | 提名委員會 | 薪酬委員會 | | 蔡東晨先生 | | C | | | 王波先生 | M | M | M | | CHEN Chuan先生 | M | M | M | | 歐振國先生 | C | | C | | 李泉女士 | | M | | 附註： C 有關董事委員會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 (1) 委任執行董事； (2) 更換副主席、首席執行官及授權代表； 及 (3) 委任首席運營官 （股份代號：1093） （於香港註冊成立之有限公司） 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）謹 此 宣 佈，自2025年12月19日起生效： (3) 魏青杰先生（「魏先生」）獲委任為副主席、本公司執行董事及首席運營官。 張先生已確認，彼與董事會並無意見分歧，且並不知悉任何有關其退任副主席及首席執行 官而需本公司股東關注事項。 董事會藉此機會對張先生在擔任副主席、首席執行官及授權代表之任期內作出之貢獻及領 導致以衷心謝意。 – 1 – (1) 張翠龍先生（「張先生」）因工作調動而不 再擔任董事會副主席（「副主席」 ...

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has increased by over 4%, reaching HKD 8.36 with a trading volume of HKD 579 million, following the announcement of positive results from a Phase III clinical trial for its biosimilar drug, Sichuqi You Injection [1] Group 1: Clinical Trial Results - CSPC's subsidiary, CSPC Zhongqi Biopharmaceutical Co., Ltd., announced that its drug, Sichuqi You Injection, achieved positive topline results in a Phase III clinical trial for treating moderate to severe plaque psoriasis [1] - The study met its primary endpoint, demonstrating clinical equivalence to the reference drug, Cosentyx, with good safety profiles and no new or unexpected safety signals [1] - The drug is a fully human IgG1 monoclonal antibody and is expected to meet long-term safety needs for patients [1] Group 2: Product Background - Sichuqi You Injection is a biosimilar to Cosentyx, which has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized in the medical community [1]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has increased by over 4%, currently trading at HKD 8.36 with a transaction volume of HKD 579 million, following the announcement of positive results from a Phase III clinical trial for its biosimilar drug, Secukinumab Injection [1] Group 1: Clinical Trial Results - CSPC's subsidiary, CSPC Zhongqi Pharmaceutical Co., Ltd., has developed Secukinumab Injection, which has shown clinical equivalence to the reference drug in a Phase III trial for moderate to severe plaque psoriasis [1] - The key study achieved its primary endpoint and demonstrated positive topline results, indicating that the product is clinically equivalent to the reference drug with good safety profiles [1] - No new or unexpected safety signals were reported, suggesting that the product may meet long-term safety requirements for patients [1] Group 2: Product Information - Secukinumab Injection is a fully human IgG1 monoclonal antibody and is a biosimilar to Cosentyx, which has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized, supporting the potential market acceptance of the biosimilar [1]

Company News - Emperor Capital (00717.HK) reported total revenue of approximately HKD 730 million for the year ending September 30, 2025, representing a year-on-year increase of 37.3%. Net profit reached approximately HKD 147 million, up 121.4% year-on-year [2] - New Special Energy (01799.HK) plans to sell a 79.92% stake in Xinjiang Wind Power New Energy Partnership for approximately HKD 1.337 billion to facilitate a REITs issuance [2] - Bay Area Development (00737.HK) signed a construction contract for the Shenzhen section with a contract value of RMB 1.448 billion [2] - Weichai Power (03393.HK) won a bid for the Brazil CPFL project with a contract amount exceeding HKD 80 million [3] - WuXi AppTec (02359.HK) invested approximately EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [3] - Joy Spreader Group (02473.HK) established a long-term strategic cooperation with New Stone Technology in areas such as autonomous vehicle procurement and market promotion [3] - Fosun Pharma (02196.HK) signed a cooperation and option agreement with Clavis Bio to jointly advance preclinical development of selected target compounds [3] - CSPC Pharmaceutical Group (01093.HK) reported top-line analysis data from the Phase III clinical trial of its drug, Truxima [3] - Yihai International (01662.HK) announced a strategic cooperation between Trio AI and HGC [4] Financing and Buyback Activities - Zhi Yuan Holdings (00990.HK) plans to issue a total of 515 million new shares at a discount of approximately 1.4%, aiming to raise about HKD 355.3 million [5] - Tencent Holdings (00700.HK) repurchased 1.055 million shares for HKD 636 million, with buyback prices ranging from HKD 599.5 to HKD 605.5 [5] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for HKD 151 million, with buyback prices between HKD 40.12 and HKD 40.24 [6] - COSCO Shipping Holdings (01919.HK) repurchased 5.9 million shares for HKD 80.6 million, with buyback prices from HKD 13.52 to HKD 13.76 [7] - Kuaishou-W (01024.HK) repurchased 1.235 million shares for HKD 80.2 million, with buyback prices ranging from HKD 64.35 to HKD 65.60 [7] - Geely Automobile (00175.HK) repurchased 1.908 million shares for HKD 31.8 million, with buyback prices between HKD 16.26 and HKD 16.8 [8]

Core Viewpoint - The announcement highlights the successful top-line analysis data from a Phase III clinical trial of the drug Secukinumab Injection, developed by the subsidiary of the company, for the treatment of moderate to severe plaque psoriasis, indicating its clinical equivalence to an existing treatment [1][2] Group 1: Product Development - The product is a fully human IgG1 monoclonal antibody drug, serving as a biosimilar to Cosentyx, which has been approved in China for multiple indications including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The company follows the research guidelines for biosimilars and conducted a head-to-head equivalence study to validate the product's efficacy against Cosentyx in treating moderate to severe plaque psoriasis [2] Group 2: Clinical Trial Details - The Phase III clinical trial was a multicenter, randomized, double-blind, parallel, positive-controlled study, aimed at verifying the consistency of treatment efficacy between the product and Cosentyx [2] - The trial enrolled patients with moderate to severe plaque psoriasis, randomly assigning them in a 1:1 ratio to either the test group (the product) or the control group (Cosentyx), with the primary endpoint being the proportion of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI) score by week 12 [2] - The key study achieved its pre-set primary endpoint, demonstrating clinical equivalence to Cosentyx, with good safety profiles and no new or unexpected safety signals, indicating potential for long-term patient safety [2]